Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) Stock Short Interest Report for October

Retension Pharmaceuticals, Inc. (NASDAQ:RTSN) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totaling 62,034 shares. Approximately 0.7% of the company’s shares are short sold. Based on an average daily volume of 118,161 shares, the days-to-cover ratio is currently 0.5 days.

Retension Pharmaceuticals Trading Down 4.0%

Shares of NASDAQ RTSN traded down $0.47 during trading on Friday, hitting $11.36. 58,701 shares of the company traded hands, compared to its average volume of 162,176. Retension Pharmaceuticals has a fifty-two week low of $9.66 and a fifty-two week high of $18.64.

Insider Buying and Selling

In other news, Director Franklin M. Berger purchased 10,000 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were purchased at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the transaction, the director owned 10,000 shares of the company’s stock, valued at approximately $120,000. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Eric L. Keller acquired 20,800 shares of the stock in a transaction dated Tuesday, October 13th. The stock was acquired at an average cost of $12.00 per share, with a total value of $249,600.00. Following the completion of the transaction, the chief executive officer owned 423,377 shares in the company, valued at approximately $5,080,524. This represents a 5.17% increase in their position. The SEC filing for this purchase provides additional information.

Retension Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.